TG THERAPEUTICS, INC.(TGTX)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
TG THERAPEUTICS, INC. (TGTX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TGTX at 69.3/100 on a 32-signal composite quality model, placing it at rank #277 of 2,960 stocks — the top 10% of the AI-ranked universe. TGTX scores in the top quartile across balance sheet strength (98.9), profitability (98.4), revenue growth (94.8). Areas of concern include free cash flow (32.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TG THERAPEUTICS, INC. reports quarterly revenue of $240.3M, net income of $7.8M, free cash flow of $39.0M. Top institutional holders of TGTX by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, STATE STREET, based on the most recent SEC filings. TGTX trades on the Nasdaq exchange and files with the SEC under CIK 1001316. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TGTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TG THERAPEUTICS, INC. directly from SEC EDGAR.
AI Quality Score
69.3/100
AI Rank
#277
Revenue
$240.3M
Net Income
$7.8M
Free Cash Flow
$39.0M
TGTX key financials by period
TG THERAPEUTICS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$616.3M
$447.2M
20.0%
FY 2024
10-K
$329.0M
$23.4M
12.7%
FY 2023
10-K
$233.7M
$12.7M
8.8%
FY 2022
10-K
$2.8M
$-223.8M
—
FY 2021
10-K
$6.7M
$-348.1M
—
FY 2020
10-K
$152.0K
—
—
Institutions holding TGTX
Institutional investors reporting a position in TG THERAPEUTICS, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue grew to $240.3M from $141.1M on BRIUMVI uptake, but net income fell to $7.8M from $28.2M as R&D and interest expense surged.
Biggest Revenue Drivers
Product revenue, net$235.8M
Greater market penetration of BRIUMVI in the United States and commercial product sales supplied to Neuraxpharm
License, milestone, royalty and other revenue$4.5M
$3.6 million of Neuraxpharm royalty revenue plus $0.9 million for development and regulatory activities
Biggest Revenue Drivers
Total revenue: $240.3M
Product revenue, net$235.8M
Greater market penetration of BRIUMVI in the United States and commercial product sales supplied to Neuraxpharm
Within Product revenue, net
U.S. BRIUMVI net product sales$227.7M
Net product sales of BRIUMVI in the United States, versus $138.8 million a year ago
Sales to Neuraxpharm (ex-U.S. partner)$8.1M
Optional purchases of BRIUMVI supplied under the Commercialization Agreement; there were no such sales in the prior-year quarter
License, milestone, royalty and other revenue$4.5M
$3.6 million of Neuraxpharm royalty revenue plus $0.9 million for development and regulatory activities
Largest Expense Items
Other research and development$87.3M
Increase from $27.5 million driven primarily by manufacturing expense for subcutaneous development work and other R&D manufacturing activities
Other selling, general and administrative$62.3M
Increase from $43.5 million due to marketing and media spend and personnel-related costs supporting BRIUMVI commercialization
Cost of revenue$41.2M
Increase from $18.9 million driven by growth in BRIUMVI U.S. sales volume and sales to Neuraxpharm; includes $24.4 million LFB royalty
Interest expense$16.6M
Increase from $6.7 million mainly due to the First Amendment to the Financing Agreement with Blue Owl Capital
Margins: Gross margin on BRIUMVI U.S. net product revenue remained approximately 87% in the quarter; total gross margin was approximately 83%, reflecting Neuraxpharm sales and other revenue that carry different margins.
Watch Items from the Filing
Four specialty distributors accounted for 40%, 29%, 19% and 12% of gross product revenue in the quarter, and 36%, 23%, 28% and 12% of product accounts receivable.
March 2026 refinancing replaced the $250 million term loan with a $750 million Blue Owl facility maturing 2031; loan payable non-current is $745.4 million and secured by substantially all assets.
Net income fell to $7.8 million from $28.2 million despite revenue growth; the quarterly effective tax rate rose to 24.0% from 8.8% after the valuation allowance release.
Non-cancelable purchase commitments total $219.8 million, with $105.7 million and $114.1 million expected in 2027 and 2028; the sole bulk drug substance supplier is located outside the U.S., exposing inventory to tariffs.
Phase 3 ENHANCE met its primary endpoint for a single 600 mg initiation infusion, and subcutaneous ublituximab Phase 3 topline is expected around year-end 2026 or Q1 2027.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
